Hamid Hamzeiy

Hamid Hamzeiy

Auto-generated profile, based on publicly available information

Hamid Hamzeiy

Computational Systems Biochemistry Research Group, Max Planck Institute of Biochemistry, Martinsried, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PRParals Registry
Parals Registry
WRWouter van Rheenen
Wouter van Rheenen
SGSLALOM Group
SLALOM Group
SRSlap Registry
Slap Registry
FCFALS Sequencing Consortium
FALS Sequencing Consortium
JVJan H Veldink
Jan H Veldink

8 July 2021 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
PSPavel Sinitcyn
Pavel Sinitcyn
HHHamid Hamzeiy
Hamid Hamzeiy
FSFavio Salinas Soto
Favio Salinas Soto
DIDaniel Itzhak
Daniel Itzhak
FMFrank McCarthy
Frank McCarthy
JCJürgen Cox
Jürgen Cox
MaxDIA is a software platform for analyzing data-independent acquisition (DIA) proteomics data within the MaxQuant software environment. Using spectral libraries, MaxDIA achieves deep proteome coverage with substantially better coefficients of variation in protein quantification than other software. MaxDIA is equipped with accurate false discovery rate (FDR) estimates on both library-to-DIA match and protein levels, including when using whole-proteome predicted spectral libraries. This is the foundation of discovery DIA—hypothesis-free analysis of DIA samples without library and with reliable FDR control. MaxDIA performs three- or four-dimensional feature detection of fragment data, and scoring of matches is augmented by machine learning on the features of an identification. MaxDIA’s bootstrap DIA workflow performs multiple rounds of matching with increasing quality of recalibration and stringency of matching to the library. Combining MaxDIA with two new technologies—BoxCar acquisition and trapped ion mobility spectrometry—both lead to deep and accurate proteome quantification.

11 November 2013
Verified
Book Chapter
Closed access
PDF file
HHHamid Hamzeiy
Hamid Hamzeiy
JAJens Allmer
Jens Allmer
MYMalik Yousef
Malik Yousef

1 December 2016 in Neurobiology of Disease
Verified
Journal Article
Closed access
NSNesli Ece Sen
Nesli Ece Sen
JDJessica Drost
Jessica Drost
SGSuzana Gispert
Suzana Gispert
STSylvia Torres-Odio
Sylvia Torres-Odio
EDEwa Damrath
Ewa Damrath
GAGeorg Auburger
Georg Auburger

9 February 2018 in Neurodegenerative Diseases
Verified
Journal Article
Closed access
PDF file
HHHamid Hamzeiy
Hamid Hamzeiy
DSDoruk Savaş
Doruk Savaş
CTCeren Tunca
Ceren Tunca
NŞNesli Ece Şen
Nesli Ece Şen
AEAslı Gündoğdu Eken
Aslı Gündoğdu Eken
ABA. Nazlı Başak
A. Nazlı Başak
Adult-onset neurological disorders are caused and influenced by a multitude of different factors, including epigenetic modifications. Here, using an ELISA kit selected upon careful testing, we investigated global 5-methylcytosine (5-mC) levels in sporadic and familial amyotrophic lateral sclerosis (sALS and fALS), spinocerebellar ataxia types 1 and 2 (SCA1 and SCA2), Huntington’s disease, Friedreich’s ataxia, and myotonic dystrophy type 1. We report a significant elevation in global 5-mC levels of about 2–7% on average for sALS (p < 0.01 [F(1, 243) = 9.159, p = 0.0027]) and various forms of fALS along with SCA1 (p < 0.01 [F(1, 83) = 11.285], p = 0.0012) and SCA2 (p < 0.001 [F(1, 122) = 29.996, p = 0.0001]) when compared to age- and sex-matched healthy controls. C9orf72 expansion carrier ALS patients exhibit the highest global 5-mC levels along with C9orf72 promoter hypermethylation. We failed to measure global 5-hydroxymethylcytosine (5-hmC) levels in blood, probably due to the very low levels of 5-hmC and the limitations of the commercially available ELISA kits. Our results point towards a role for epigenetics modification in ALS, SCA1, and SCA2, and help conclude a dispute on the global 5-mC levels in sALS blood.

24 June 2020 in Human Mutation
Verified
Journal Article
Open access
PDF file
CTCeren Tunca
Ceren Tunca
TŞTuncay Şeker
Tuncay Şeker
FAFulya Akçimen
Fulya Akçimen
CCCemre Coşkun
Cemre Coşkun
EBElif Bayraktar
Elif Bayraktar
A. Nazlı BaşakA. Nazlı Başak
A. Nazlı Başak
The last decade has proven that amyotrophic lateral sclerosis (ALS) is clinically and genetically heterogeneous, and that the genetic component in sporadic cases might be stronger than expected. This study investigates 1,200 patients to revisit ALS in the ethnically heterogeneous yet inbred Turkish population. Familial ALS (fALS) accounts for 20% of our cases. The rates of consanguinity are 30% in fALS and 23% in sporadic ALS (sALS). Major ALS genes explained the disease cause in only 35% of fALS, as compared with ~70% in Europe and North America. Whole exome sequencing resulted in a discovery rate of 42% (53/127). Whole genome analyses in 623 sALS cases and 142 population controls, sequenced within Project MinE, revealed well‐established fALS gene variants, solidifying the concept of incomplete penetrance in ALS. Genome‐wide association studies (GWAS) with whole genome sequencing data did not indicate a new risk locus. Coupling GWAS with a coexpression network of disease‐associated candidates, points to a significant enrichment for cell cycle‐ and division‐related genes. Within this network, literature text‐mining highlights DECR1 , ATL1 , HDAC2 , GEMIN4 , and HNRNPA3 as important genes. Finally, information on ALS‐related gene variants in the Turkish cohort sequenced within Project MinE was compiled in the GeNDAL variant browser (www.gendal.org).